Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

Inclusion Criteria: 1. 18 years of age or older 2. HIV-infected 3. Evidence of durable virologic suppression, i.e., must have HIV-1 RNA \< 400 copies/ml at study entry and for at least 12 weeks prior to entry 4. On a stable antiretroviral (ARV) regimen, i.e., on the same ARV for at least 12 weeks prior to study entry 5. No intention to stop or modify ARV regimen during the study period Exclusion Criteria: 1. Current pregnancy or breast feeding, or women of child bearing age who refuse or are unable to use appropriate methods for contraception during the study period 2. Any of the following conditions: diabetes (2 fasting glucose levels \> 126 mg/dL or confirmed random glucose level \> 200), creatinine clearance \< 50, aspirin-sensitive asthma, COPD, history of bleeding gastric or duodenal ulcer, hepatic dysfunction, active hepatitis B or C, and any active infectious or inflammatory condition 3. Need for regular use of any of the following medications: salsalate, aspirin, non-steroidal antiinflammatories (NSAIDS), corticosteroids, warfarin or other anticoagulation therapy, phenytoin, valproic acid, carbonic anhydrase inhibitors, lithium, probenecid or sulfinpyrazone 4. Consumption of alcohol on a daily basis 5. Active use of illicit drugs 6. Unable to attend follow-up appointments 7. Allergy to any salicylic acid-containing medication or salsalate 8. AST or ALT \> 2 upper limit of normal (ULN) within 6 months prior to study entry